Insider buying last 90 days
No open-market insider purchases were filed for RYTM in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every RYTM insider filing, plotted on the chart in Gekko.Open RYTM in Gekko
NASDAQ: RYTM
Rhythm Pharmaceuticals (RYTM) Stock Analysis & Forecast
Sep 28 close
$98.56−0.10 (−0.1%)
Gekko Brief
AI summaryRhythm Pharmaceuticals this week drew attention from a shareholder litigation probe, with Kuehn Law, PLLC investigating company officers and directors over possible breaches of fiduciary duty tied to self-dealing. Separately, the company announced Health Canada approval of IMCIVREE (setmelanotide) for weight management in adult and pediatric patients aged 4 and older with acquired hypothalamic obesity, extending the drug's approved use into a new market.
RYTM closed at $98.56, down 0.1%, sitting between its 50-day average of $106.23 and 200-day average of $99.24, with the one-month return at -12.4% and the six-month return at 30%. The GekkoIndex reads 67.3, placing the stock in the Accumulation zone, though the reading has slipped 2 points over five days. Price sits 17.4% below Gekko Fair Value of $119.27.
Rhythm's next earnings report is scheduled for 3 November 2026, before the open, 35 days away and outside a typical 20-trading-day hold; the prior quarter beat estimates with an EPS of -0.73 against a -0.82 estimate and a 2.1% reaction. No insider, Congress, or unusual options activity appears in the current windows. Analyst coverage stands at 13 buy and 1 hold across 14 firms, with a consensus target of $138.59. Seasonality over the next 20 trading days has averaged -0.9% across 5 years, rising in 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Rhythm Pharmaceuticals price vs fair value
Close $98.56200-day averageGekko Fair Value $119.27
Rhythm Pharmaceuticals quick facts
- Market cap
- $6.76B
- P/E ratio
- —
- Forward P/E
- 526.3
- EPS, TTM
- −$3.12
- Revenue, TTM
- $239.9M
- Profit margin
- -85.6%
- Dividend yield
- —
- Beta
- 1.97
- Volume
- 840,582 avg 628,675
- 1-year return
- −0.6%
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±10.2%
- 50-day average
- $106.23
- 200-day average
- $99.24
- Next earnings
- Nov 3 before open
- Shares outstanding
- 68.59M
Rhythm Pharmaceuticals swing-trade checklist
Rhythm Pharmaceuticals scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $98.56 sits between the 50-day ($106.23) and 200-day ($99.24) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.3, Accumulation
Reading 67.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
17.4% below
Price is 17.4% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 35 days
Next report Nov 3, 2026, 35 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−0.9% on average
From this point in the calendar, the next 20 trading days averaged −0.9% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Rhythm Pharmaceuticals stock chart and price history
Rhythm Pharmaceuticals closed at $98.56 on Sep 28, 2026, −0.6% over the past year, inside a 52-week range of $74.50 to $122.20.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.4%
- 3 months
- −10.4%
- 6 months
- +30.0%
- 1 year
- −0.6%
The full RYTM chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open RYTM in Gekko
Follow Rhythm Pharmaceuticals through every session
Put RYTM on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track RYTM in GekkoFree for 7 days. No credit card required.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals works on medicines for rare genetic disorders that lead to obesity, combining research, development and the sale of approved treatments. Its main product, IMCIVREE, acts on the melanocortin-4 receptor pathway and is used for obesity linked to POMC, PCSK1 or LEPR deficiencies, as well as for patients with Bardet-Biedl and Alström syndromes. This treatment forms the core of what the company is recognized for in the market.
Beyond its marketed therapy, the company is studying the same active compound, setmelanotide, in Phase II trials aimed at additional conditions, including heterozygous POMC or LEPR deficiency, SRC1 and SH2B1 deficiencies, MC4 receptor deficiency, and obesity tied to Smith-Magenis syndrome and related POMC epigenetic disorders. It also participates in a collaborative research arrangement with the Clinical Registry Investigating Bardet-Biedl Syndrome, connecting its pipeline work to patients affected by these conditions.
The company is based in Boston, Massachusetts, and traces its founding to 2008, having operated originally under the name Rhythm Metabolic before adopting its current name in 2015. Its shares are listed on the NASDAQ under the ticker RYTM.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- rhythmtx.com
Rhythm Pharmaceuticals GekkoIndex: the smart money zone
Rhythm Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.3, in the Accumulation zone, down 2 points over five sessions.
67.3Accumulation
Down 2 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 6 | Too few readings yet | |||
| Accumulation (current zone) | 203 | +2.0% | +4.4% | ||
| Neutral | 412 | +0.6% | +3.4% | ||
| Distribution | 44 | −1.2% | −4.3% | ||
| Selling | 7 | Too few readings yet | |||
Average RYTM share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the RYTM price, zone by zone.Track RYTM in Gekko
Is Rhythm Pharmaceuticals stock overvalued? Gekko Fair Value
Rhythm Pharmaceuticals trades 17.4% below Gekko Fair Value of $119.27, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Rhythm Pharmaceuticals shares are worth, recalculated every trading day.
$119.27
Gekko Fair Value, Sep 26, 2026
17.4% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open RYTM in Gekko
Rhythm Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Rhythm Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in RYTM were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for RYTM, plotted on the chart in Gekko.Open RYTM in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds RYTM.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Rhythm Pharmaceuticals earnings: next date and track record
Rhythm Pharmaceuticals reports on Nov 3, 2026, before the open (35 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 3, 2026
Expected before the open, 35 days away
- EPS estimate
- −$0.72
- Revenue estimate
- $84.84M
5 of 8reports beat the EPS estimate
±6.4%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Mar 4, 2026 AI summary
- What they said
- Rhythm Pharmaceuticals provided a broadly positive earnings call highlighting strong commercial performance of IMCIVREE, significant revenue growth, international expansion, clinical development progress for next-generation MC4R agonists (bivamelagon and RM-718), and preparation for an acquired hypothalamic obesity (HO) launch pending the March 20 PDUFA decision. Management reviewed Phase 2/extended data for bivamelagon showing persistent BMI reductions and consistent safety, described plans to present full 52-week data mid-year, discussed regulatory feedback that Phase 3 for new molecules will likely require year-long trials similar to setmelanotide, and reiterated progress across EMANATE (gene-specific cohorts) and other clinical programs. Financially, Q4 2025 product revenues were $57.3M (+12% sequential) and FY2025 revenues were $194.8M (+~50% YoY). Management noted an inventory build at specialty pharmacies that could dampen Q1 demand and described ongoing payer engagement and salesforce expansion to prepare for HO launch and broaden access for BBS and other indications.
- Guidance
- Operational/regulatory guidance and forward-looking items provided: - PDUFA goal date for Acquired Hypothalamic Obesity: March 20, 2026 (expectation of regulatory decision and potential launch) - Expect to present full 52-week bivamelagon data at a medical meeting mid-year - Plan to include the Japanese cohort data in the regulatory submission for HO prior to the PDUFA decision - Anticipation of a year-long Phase 3 requirement for new small molecules (FDA feedback), implying similar Phase 3 duration for bivamelagon and possibly RM-718 - No specific financial guidance or revenue/earnings projections were provided.
- Risks flagged
- Mentioned or implied risks: - Inventory build / pull-forward of shipments at specialty pharmacy could dampen Q1 demand - Regulatory risk: FDA feedback that new molecules will likely require year-long Phase 3 trials (longer development timelines and costs) - Enrollment challenges for rare genetic cohorts (under-enrollment risk for leptin receptor cohort; many variants are VUS) - Payer coverage and reimbursement timing (CNT and policy processes could delay access) - Competitive/clinical complexity: interaction with GLP-1s and uncertainty about real-world combination effects - Execution risk in scaling launches internationally
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 4, 2026 | −$0.73 est −$0.82 | $57.25M est $56.21M | +2.1% |
| Nov 4, 2025 | −$0.82 est −$0.72 | $51.30M est $55.98M | −12.5% |
| Aug 5, 2025 | −$0.75 est −$0.66 | $48.50M est $51.33M | −0.3% |
| May 5, 2025 | −$0.81 est −$2.16 | $32.70M est $43.28M | −2.0% |
| Feb 20, 2025 | −$0.72 est −$0.73 | — | −3.3% |
| Nov 5, 2024 | −$0.73 est −$0.80 | $33.25M est $35.93M | +18.2% |
| Aug 6, 2024 | −$0.69 est −$0.71 | $29.08M est $28.79M | −1.1% |
| May 7, 2024 | −$2.35 est −$2.16 | $25.97M est $28.79M | −11.3% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Rhythm Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Rhythm Pharmaceuticals is $138.59, +40.6% from the last close, from 14 firms rating the stock in the last 90 days.
$138.59consensus 12-month target, +40.6% from the last close
Now $98.56Avg $138.59
Low $120High $160
Each firm’s latest rating in the last 90 days: 14 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 17 | Wolfe Research | — | — |
| Sep 15 | J.P. Morgan | — | — |
| Sep 14 | Leerink Partners | $133 | +34.9% |
| Sep 14 | Leerink Partners | $133 | +34.9% |
| Sep 14 | RBC Capital | $155 | +57.3% |
+4.4%average 20-day move after past Accumulation readings
−0.9%average move over the next 20 trading days in the last 5 years
±3.8%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Rhythm Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Rhythm Pharmaceuticals averaged −0.9% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 2 of 5 |
| Next 10 trading days | −2.3% | 2 of 5 |
| Next 15 trading days | −3.2% | 1 of 5 |
| Next 20 trading days | −0.9% | 2 of 5 |
| Next 30 trading days | +12.3% | 4 of 5 |
For scale, RYTM’s typical 20-trading-day move in either direction is about 10.2%.
Rhythm Pharmaceuticals market cap and key statistics
Rhythm Pharmaceuticals’s market cap is $6.76B and revenue of $239.9M over the last twelve months.
Valuation
- Market cap
- $6.76B
- Forward P/E
- 526.3
- EPS, TTM
- −$3.12
- Gekko Fair Value
- $119.27
Trading
- Volume
- 840,582
- Avg volume, 20 days
- 628,675
- 52-week high
- $122.20
- 52-week low
- $74.50
- Shares outstanding
- 68.59M
Financials
- Revenue, TTM
- $239.9M
- Profit margin
- -85.6%
- Return on equity
- -117.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.97
- Typical daily move
- ±3.8%
- Typical 20-day move
- ±10.2%
Rhythm Pharmaceuticals stock news this week
Coverage of Rhythm Pharmaceuticals this week reads positive: 2 positive, 1 neutral and 1 negative headlines.
- Investigation launched into Rhythm Pharmaceuticals' executives for possible self-dealing harming shareholdersPluang, Sep 28
- Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmPRNewsWire, Sep 28
- ETFs Investing in Rhythm Pharmaceuticals, Inc. StocksTradingView, Sep 27
- Will Canada Approval Change Rhythm Pharmaceuticals' (RYTM) NarrativeSimply Wall Street, Sep 24
- Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic ObesityGlobeNewswire, Sep 23
Rhythm Pharmaceuticals peers
Rhythm Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Rhythm Pharmaceuticals stock FAQ
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $6.76B at the Sep 28, 2026 close of $98.56, with 68.59M shares outstanding.
What is the Rhythm Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Rhythm Pharmaceuticals is $138.59, +40.6% from the last close. Of the 14 firms that rated the stock in the last 90 days, 13 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Rhythm Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Rhythm Pharmaceuticals is undervalued: the Sep 28, 2026 close of $98.56 is 17.4% below Gekko Fair Value of $119.27. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Rhythm Pharmaceuticals report earnings next?
Rhythm Pharmaceuticals is expected to report on Nov 3, 2026, before the market opens (35 days away). Analysts expect earnings of −$0.72 per share on revenue of $84.84M. Rhythm Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 6.4% on average across the report.
What is Rhythm Pharmaceuticals’s 52-week high and low?
Rhythm Pharmaceuticals’s 52-week high is $122.20 and its 52-week low is $74.50; it closed at $98.56 on Sep 28, 2026, −0.6% over the past year.
Is Rhythm Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Rhythm Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.